Table 1.
Gene | Risk for PCA* | Risk for aggressive PCA features*,‡ | *+Risk for early-onset PCA (age at diagnosis < 65)*,§ | PCA-specific outcomes† |
---|---|---|---|---|
BRCA1 | 1.07–3.81 [26,53,89–92] | -- | 1.82 [90] | 5.16 [56] |
BRCA2 | 3.18–8.6 [26,56,57,89,93–95] | 3.18–4.38 [30,55,96] | 7.33 [89] | HR for death 2.4–5.48 [56,96–98], decreased survival [31] |
Mismatch repair genes | 1.99–3.67 [38,99] | -- | 2.48 [38] | -- |
HOXB13 | 2.8–8.47 [41,44,47,50] | -- | 2.7–10.11 [41,44,47,50,100] | -- |
Risks are a combination of odds ratios, relative risks, hazard ratios, or standardized incidence ratios depending on the study. Risks vary based on strength of family history reported.
Outcomes are a combination of survival estimates or mortality depending on the study.
Definition of aggressive prostate cancer features include Gleason score ≥ 7, depending on the study. Additional studies have described an association of BRCA1 and BRCA2 in particular to features of aggressiveness. The table highlights those studies with reported risk estimates.
While definitions for early-onset prostate cancer can vary, risks are reported for age at diagnosis < 65 years to encompass the majority of studies with an age-related focus.